Gregory Lacy, MD
Urology · New Haven, CTNPI 1073564829
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,937 of the $10,855 with a category attached, or 63.9%. 19 manufacturers reported payments, led by Boston Scientific at 59.8% of the total.
Across 124 payments — averaging $87.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$6K
- KARL Storz Endoscopy-america$889
- Cook Incorporated$857
- Cook Medical LLC$762
- Teleflex LLC$608
- Johnson & Johnson$411
- plus $839 from 13 others
What the payments were for
- Travel & lodging$3,91836%
- Food & beverage$6,93764%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 57 | $6,490 |
| KARL Storz Endoscopy-america | 12 | $889 |
| Cook Incorporated | 2 | $857 |
| Cook Medical LLC | 18 | $762 |
| Teleflex LLC | 6 | $608 |
| Johnson & Johnson(2 entities) | 6 | $411 |
| Kerecis Limited | 1 | $172 |
| Neotract Inc. | 1 | $131 |
| Photocure Inc | 3 | $130 |
| Astellas Pharma US Inc | 4 | $107 |
| 180 Medical, Inc. | 4 | $79 |
| Urogen Pharma, Inc. | 2 | $54 |
| Pfizer | 2 | $45 |
| Sumitomo Pharma America, Inc. | 1 | $31 |
| Progenics Pharmaceuticals, Inc. | 1 | $21 |
| Coloplast | 1 | $21 |
| Ambu Inc. | 1 | $18 |
| Laborie Medical Technologies Corp. | 1 | $17 |
| Hollister Incorporated | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- S~Curve$931
- GENERAL KIDNEY STONE DISEASE$890
- AMS$734
- Kerecis SurgiClose$687
- Moses$536
- LithoVue$451
- UroLift$363
- REZUM$238
- Kerecis GraftGuide$172
- N/A$149
- Moses 550 DFL$149
- Lumenis Pulse 120H$143
- CUTTING LOOP, BIPOLAR, 24/26 FR.$138
- Barrigel$134
- ECHELON ENDOPATH$132
- Megadyne$132
- ADVANCE$125
- SURGIFLO Hemostatic Matrix$122
- Cook$121
- Echelon Flex$120
How this compares
$10,855 in reported general payments places this provider in the 85th percentile of 156 urology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 114 | $62,538 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 114 | $2,206 |
| Tamsulosin Hcl | 196 | $1,619 |
| Solifenacin Succinate | 62 | $1,227 |
| Finasteride | 123 | $1,087 |
| Oxybutynin Chloride ErOxybutynin Chloride | 122 | $725 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 21 | $666 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 13 | $225 |
| Ciprofloxacin Hcl | 54 | $209 |
| Ibuprofen | 54 | $183 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 50 | $109 |
| Levofloxacin | 16 | $48 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $107 | $62,538114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 156 urology providers in Connecticut.
Other urology in New Haven
- Daniel KellnerNew Haven$122K
- Preston SprenkleNew Haven$57K
- Stanton HonigNew Haven$40K
- Michael LeapmanNew Haven$21K
- Jason LeeNew Haven$19K
- Leslie RickeyNew Haven$17K
- Fady GhaliNew Haven$10K
- Guy ManettiNew Haven$7K
- Wei Shen TanNew Haven$6K
- Ganesh SanekommuNew Haven$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.